Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-04-12
1998-06-02
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514 13, 514 14, 514 15, 514 16, 514 17, 530317, 530324, 530325, 530326, 530327, 530328, 530329, A61K 3808, A61K 3810, A61K 3812, A61K 3816
Patent
active
057599963
ABSTRACT:
The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter .alpha..sub.v .beta..sub.3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.
REFERENCES:
patent: 4517686 (1985-05-01), Ruoslahti et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4614517 (1986-09-01), Ruoslahti et al.
patent: 4661111 (1987-04-01), Ruoslahti et al.
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 5041380 (1991-08-01), Ruoslahti et al.
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5227469 (1993-07-01), Lazarus et al.
Ross et al. Interactions Between the Bone Matrix Proteins . . . J. Biol. Chem. 5 May 1993, vol. 268, No. 13, pp. 9901-9907.
Brooks et al, Requirement of Vascular Integrin . . . Science 22 Apr. 1994, vol. 264, pp. 569-571.
Brooks et al. Integrin .alpha..sub.v .beta..sub.3 Antagonists Promote Tumor . . . Cell. 30 Dec. 1994, vol. 79, pp. 1157-1164.
Fisher et al. Inhibition of Osteoclastic Bone Resorption . . . Endocrinology, Mar. 1993, vol. 132, No. 3, pp. 1411-1413.
Gan et al. Echistatin. J. Biol. Chem. 25 Dec. 1988, vol. 263, pp. 19827-19832.
Choi, Eric t. et al., "Inhibition of Neointimal Hyperplasia by Blocking .alpha..sub.v .beta..sub.3 Integrin with a Small Peptide Antagonist GpenGRGDSPCA." J. Vascular Surg. 19:125-134 (1994).
Matsuno, Hiroyuki. et al., "Inhibition of Integrin Function by a Cyclic RGD-Containing Peptide Prevents Neointima Formation." Circulation 90:2203-2206 (1994).
Aumailley et al., "Arg-Gly-Asp Constrained within Cyclic Pentapeptides Strong and Selective Inhibitors of Cell Adhesion to Vitronectin and Laminin Fragment P1," FEBS Letters 291(1):50-54 (1991).
Fauchere et al., "Modulation of the Activity and Assessment of the Receptor Selectivity in a Series of New RGD-containing Peptides," Int'l J. Peptide & Protein Res. 42(5):440-444 (1993).
PCT Search Report (dated 9 Nov. 1995), International application No. PCT/US95/04741.
Cheng Soan
Ingram Ronald
Mullen Daniel
Tschopp Juerg F.
La Jolla Cancer Research Center
Russel Jeffrey E.
LandOfFree
Peptides useful for altering .alpha..sub.v .beta..sub.3 -mediate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides useful for altering .alpha..sub.v .beta..sub.3 -mediate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides useful for altering .alpha..sub.v .beta..sub.3 -mediate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459780